R
Reduced Trial (with Vascepa)
Study / ResearchMentioned in 1 video
A large randomized control trial demonstrating that high EPA supplementation (Vascepa) led to a 25% lower risk of major adverse cardiac events.
A large randomized control trial demonstrating that high EPA supplementation (Vascepa) led to a 25% lower risk of major adverse cardiac events.